Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim PharmafiledCriticalBoehringer Ingelheim Pharma
Priority to UY26390ApriorityCriticalpatent/UY26390A1/en
Publication of UY26390A1publicationCriticalpatent/UY26390A1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
El presente invento se refiere a indolinonas sustituidas en posición 5 de la fórmula general (I) en la que R1 hasta R5 y X están definidos como en la reivindicación 1, sus isómeros y sus sales, especialmente sus sales fisiológicamente compatibles, que presentan valiosas propiedades farmacológicas, especialmente un efecto inhibidor sobre diferentes quinazas y complejos de ciclinas y CDK´s sobre tirosina-quinasa de receptores, así como sobre la proliferación de células de tumores, a medicamentos que contienen estos compuestos, a su utilización y a procedimientos para su preparación.The present invention relates to 5-substituted indolinones of the general formula (I) in which R1 to R5 and X are defined as in claim 1, their isomers and their salts, especially their physiologically compatible salts, which have valuable properties Pharmacological effects, especially an inhibitory effect on different cyclin kinases and complexes and CDKs on receptor tyrosine kinase, as well as on the proliferation of tumor cells, drugs containing these compounds, their use and procedures for their preparation.
UY26390A2000-10-112000-10-11
SUBSTITUTED INDOLINONES IN POSITION 5, THEIR PREPARATION AND THEIR USE AS MEDICINES
UY26390A1
(en)
Compounds derived from pyrrole (2.3-d) pyrimidine. purin-6-yl or pyrazol (3,4-d) pyrimldine, p70 s6 kinase inhibitors; pharmaceutical composition; and use for the preparation of drugs useful in the treatment of colon adenocarcinomas and inhibition of angiogenesis.